An APOB genetic test looks for inherited variants in the gene that makes apolipoprotein B, the main structural protein on LDL and several other atherogenic lipoproteins. The same gene can cause two very different lipid disorders. Certain variants in the LDL receptor-binding region make LDL particles harder for the liver to clear, causing autosomal dominant familial hypercholesterolemia and higher lifetime heart risk. Other, usually truncating, variants reduce apoB-containing lipoprotein production and cause familial hypobetalipoproteinemia, with unusually low LDL cholesterol and possible fatty liver or fat-soluble vitamin problems. The DNA test is not the same as an apoB blood test: the blood test counts atherogenic particles, while genetic testing identifies an inherited mechanism. Interpretation must therefore consider the exact variant type and location, untreated LDL cholesterol, apoB concentration, triglycerides, liver findings, and family history. A report that simply says “APOB variant detected” is incomplete without a clinical classification and a statement of which APOB-related condition the variant is expected to cause.
- LDL-raising APOB variants can cause familial defective apoB-100, an inherited form of familial hypercholesterolemia.
- Protein-truncating APOB variants usually lower LDL and apoB rather than raise them and may cause hepatic steatosis.
- The apoB blood test measures particle number; the APOB genetic test identifies a DNA variant and does not replace a lipid panel.
- A pathogenic or likely pathogenic result can support targeted testing of relatives, but a VUS should not be used for predictive family testing.
- A negative APOB test does not exclude familial hypercholesterolemia because LDLR, PCSK9, polygenic risk, and secondary causes are more common explanations.
- New chest pressure, sudden shortness of breath, one-sided weakness, or difficulty speaking requires emergency care regardless of genetic status.
Table of Contents
- What APOB does in lipid metabolism
- Two opposite APOB-related disorders
- Who should consider APOB testing
- How the genetic test is performed
- Interpreting positive, negative, and uncertain results
- Treatment and monitoring after a result
- Inheritance and family testing
- ApoB blood test versus APOB genetic test
What APOB does in lipid metabolism
APOB provides instructions for two related proteins. ApoB-100 is made in the liver and remains on very-low-density lipoprotein, intermediate-density lipoprotein, LDL, and lipoprotein(a) particles. ApoB-48 is made in the intestine and is essential for chylomicrons, which transport dietary fat.
Each atherogenic particle generally carries one apoB molecule. That is why a blood apoB concentration can estimate the total number of circulating atherogenic particles. LDL cholesterol, by contrast, measures the amount of cholesterol carried within LDL particles. Two people can have the same LDL cholesterol but different particle numbers because particles vary in cholesterol content.
ApoB-100 also contains the region that binds to the LDL receptor. The liver uses this interaction to remove LDL particles from blood. If a pathogenic variant changes a critical binding site, LDL particles circulate longer and LDL cholesterol rises. This condition is often called familial defective apolipoprotein B-100.
The most historically recognized high-LDL variant is p.Arg3527Gln, also described in older literature as R3500Q because of a different numbering convention. Other variants in and near the receptor-binding region can also be disease-causing, but many APOB missense variants are harmless or uncertain. The gene is large, and location and mechanism matter.
APOB is included on many familial hypercholesterolemia genetic panels with LDLR and PCSK9. LDLR explains most genetically confirmed FH, while APOB accounts for a smaller proportion. An APOB-only test is usually reserved for a known familial variant or a very specific laboratory question.
Two opposite APOB-related disorders
A crucial feature of APOB testing is that different variant mechanisms point in opposite biochemical directions. A report must distinguish an LDL-raising variant from an LDL-lowering variant.
Familial defective apoB-100 and high LDL
Pathogenic variants that impair LDL receptor binding produce autosomal dominant hypercholesterolemia. Affected people often have elevated LDL from birth, though levels may be milder and more variable than in classic LDLR-related FH. Tendon xanthomas and premature coronary disease can occur, but they may be less common at the same age than in severe receptor-negative LDLR disease.
Risk still reflects lifelong LDL exposure. A modestly elevated LDL sustained for decades can cause significant atherosclerosis, particularly when combined with smoking, high blood pressure, diabetes, or elevated lipoprotein(a).
APOB-related familial hypobetalipoproteinemia
Protein-truncating variants, such as nonsense or frameshift changes, often shorten apoB and reduce secretion of apoB-containing particles. A person with one truncating variant commonly has total cholesterol, LDL cholesterol, and apoB below the fifth percentile. Many remain asymptomatic, but fat can accumulate in the liver because triglycerides cannot be exported efficiently in VLDL.
About 5% to 10% of heterozygous individuals may develop more significant steatohepatitis or liver disease. Obesity, insulin resistance, alcohol, and other liver stressors can increase risk.
People with pathogenic variants in both APOB copies can have severe hypobetalipoproteinemia. They may develop fat malabsorption, failure to thrive, neurologic problems, retinal degeneration, acanthocytosis, and deficiencies of vitamins A, D, E, and K. Severity depends partly on how much functional apoB the variants allow.
Why mechanism changes interpretation
A truncating variant found during an FH panel should not automatically be labeled as a cause of high LDL. Population and functional data show that loss-of-function APOB variants generally lower LDL. Conversely, a missense variant outside a recognized functional region should not be assumed to cause either disorder without strong evidence.
| APOB mechanism | Expected lipid pattern | Main health concerns |
|---|---|---|
| LDL receptor-binding defect | High LDL cholesterol, often normal triglycerides | Premature atherosclerotic cardiovascular disease |
| One truncating variant | Low LDL cholesterol and low apoB | Hepatic steatosis; occasionally progressive liver disease |
| Two severe truncating variants | Extremely low apoB-containing lipoproteins | Fat malabsorption, vitamin deficiency, neurologic and retinal complications |
Who should consider APOB testing
Testing may be appropriate for someone with a clinical picture of familial hypercholesterolemia, especially when a multigene panel is being used. Suspicion rises with untreated LDL cholesterol of 190 mg/dL or higher in an adult, high LDL in a child, premature coronary disease, tendon xanthomas, or a vertical family pattern of high cholesterol.
APOB testing is also useful when:
- A pathogenic APOB variant is already known in a biological relative
- LDL is high but LDLR testing is negative
- Several relatives have similar moderate hypercholesterolemia without severe receptor-negative features
- A laboratory needs to resolve an APOB variant found incidentally on broader sequencing
- LDL cholesterol and apoB are unexpectedly very low
- Fatty liver occurs with low LDL rather than metabolic hyperlipidemia
- A child has fat malabsorption, poor growth, neurologic signs, or fat-soluble vitamin deficiency with very low apoB
Secondary causes should be evaluated before attributing a lipid pattern to APOB. High LDL can result from hypothyroidism, nephrotic syndrome, cholestatic liver disease, diet, or medication. Low LDL can occur with malnutrition, hyperthyroidism, chronic infection, cancer, severe liver failure, or other genetic conditions.
The test is not usually helpful for a person whose only finding is a mildly high apoB blood level. ApoB concentration commonly rises with insulin resistance, obesity, high triglycerides, and ordinary polygenic risk. Genetic testing is most useful when the phenotype is severe, familial, unusually early, or biologically distinctive.
Testing should begin with the person whose lipid abnormality is clearest. Testing an unaffected relative first can produce an uncertain result without showing whether it explains the family’s condition.
How the genetic test is performed
A blood or saliva sample provides DNA. Fasting is not required, and lipid-lowering medication does not change the genetic result. The clinician should still collect pretreatment or highest-known lipid values because treatment can hide the original phenotype.
Clinical testing may include:
- Targeted variant analysis for a known family change.
- APOB sequencing to detect single-nucleotide variants and small insertions or deletions.
- Copy-number analysis when the laboratory includes deletions or duplications.
- A dyslipidemia panel that evaluates LDLR, APOB, PCSK9, LDLRAP1, and genes for overlapping high- or low-lipid disorders.
- Exome or genome sequencing for severe, unexplained phenotypes after focused testing.
APOB is technically and interpretively challenging because it is large and highly variable. A test may identify several rare missense changes that lack evidence. More genes and more sequence do not automatically produce a better answer; they can increase the number of VUS findings.
Before testing, the clinician or genetic counselor should document a three-generation family history. Useful details include untreated LDL values, heart attacks or coronary procedures, age at events, fatty liver, unexplained low cholesterol, neurologic symptoms, and consanguinity.
Turnaround time often ranges from several weeks to a few months. A targeted familial test is generally faster and less expensive than full sequencing. Testing should use a clinical laboratory that follows recognized variant-classification standards and explains the associated phenotype for each reportable result.
Consumer DNA reports may include common APOB markers associated with small changes in lipids. These are not equivalent to a clinical diagnosis of familial hypercholesterolemia or familial hypobetalipoproteinemia. Any result with medical implications should be confirmed in a certified laboratory.
Interpreting positive, negative, and uncertain results
A useful report states the exact variant, classification, inheritance pattern, expected mechanism, and associated condition.
Pathogenic or likely pathogenic LDL-raising variant
This result supports APOB-related autosomal dominant hypercholesterolemia when the person has a compatible LDL pattern. It can justify targeted testing of first-degree relatives. It does not prove that coronary plaque is present, and it does not determine treatment by itself; measured LDL and overall risk guide care.
Pathogenic or likely pathogenic truncating variant
One truncating variant usually supports heterozygous APOB-related familial hypobetalipoproteinemia. The clinician should review liver enzymes, liver fat, diet, alcohol, body weight, and symptoms of fat-soluble vitamin deficiency. Two pathogenic variants require assessment for severe disease and confirmation that they are on opposite chromosome copies.
Variant of uncertain significance
A VUS means the available evidence cannot establish whether the variant causes disease. It should not be used to diagnose healthy relatives, stop or start medication, or explain a lipid pattern without additional evidence. Family segregation, functional assays, location in a validated domain, and repeated laboratory review may eventually clarify it.
Negative result
No reportable APOB variant was detected. In a high-LDL phenotype, LDLR, PCSK9, other genes, polygenic inheritance, or secondary causes remain possible. In a low-LDL phenotype, MTTP, SAR1B, ANGPTL3, PCSK9 loss-of-function, and other conditions may need consideration.
Conflicting result
Occasionally, one laboratory classifies a variant differently from another. The ordering clinician should compare evidence, submit updated phenotypic data, and seek review from a lipid-genetics specialist. The latest classification is not automatically the most accurate; disease-specific evidence quality matters.
The genetic result should always be reconciled with biochemistry. An alleged high-LDL APOB variant in someone with lifelong very low LDL deserves skepticism. A truncating variant in a person with severe high LDL may be incidental rather than causal.
Treatment and monitoring after a result
Management depends on which APOB-related condition is present.
High LDL from an APOB binding variant
Treatment follows FH principles. Lifestyle reduces additional risk but rarely normalizes genetically elevated LDL. A heart-healthy diet, regular activity, smoking avoidance, blood-pressure control, and diabetes prevention remain important.
Medication commonly begins with a high-intensity statin in adults. Ezetimibe, PCSK9-directed therapy, inclisiran, or bempedoic acid may be added according to LDL response, age, established cardiovascular disease, and tolerance. Children with confirmed FH often begin statin therapy in late childhood under pediatric lipid guidance.
Clinicians may also measure lipoprotein(a), assess coronary risk, and consider imaging in selected adults. The goal is to reduce cumulative apoB-particle exposure, not simply to confirm a gene result.
Low LDL from APOB truncation
Many heterozygous individuals need surveillance rather than lipid-raising treatment. Evaluation may include:
- Lipid profile and apoB concentration every one to two years
- Liver enzymes at similar intervals
- Liver ultrasound or elastography when enzymes are elevated or steatosis is suspected
- Assessment for diabetes, obesity, alcohol exposure, and other fatty-liver risks
- Fat-soluble vitamin testing when LDL is extremely low or symptoms suggest deficiency
People with biallelic disease may need a specialized diet, essential fatty acids, and high-dose vitamins, especially vitamin E, under expert supervision. Excessive unsupervised vitamin dosing can be harmful, so laboratory monitoring is essential.
Low LDL is often viewed as protective, but severe apoB deficiency can impair fat and vitamin transport. The clinical target is not to raise LDL indiscriminately; it is to prevent nutritional, neurologic, retinal, and hepatic complications.
Inheritance and family testing
Most APOB-related high-LDL and heterozygous low-LDL conditions are autosomal dominant. A person with one pathogenic variant has a 50% chance of passing it to each child. The phenotype may differ among relatives because diet, age, sex, other genes, and medical conditions modify lipid levels.
Targeted testing is preferred once the family variant is known. Relatives should also have a lipid panel because the biochemical pattern helps confirm that the variant behaves as expected and determines treatment urgency.
For an LDL-raising variant, a relative who tests positive needs age-appropriate lipid treatment and cardiovascular prevention. A relative who tests negative for a firmly established familial variant no longer has that specific inherited risk, though ordinary cholesterol screening still applies.
For a truncating variant, relatives who test positive may benefit from liver and nutritional assessment even if they feel well. Testing both parents of a child with severe hypobetalipoproteinemia can determine whether two variants were inherited in trans.
Partners may consider testing when one person has a pathogenic truncating variant and the couple wants to understand the chance of a child inheriting biallelic disease. Reproductive counseling should explain that severity depends on the exact variants and residual apoB production.
ApoB blood test versus APOB genetic test
The names are similar, but the tests serve different purposes.
| Feature | APOB genetic test | ApoB blood test |
|---|---|---|
| What is measured | DNA sequence in the APOB gene | Concentration of apoB protein in blood |
| Changes over time | Usually unchanged throughout life | Changes with metabolism, diet, illness, and treatment |
| Main use | Identify an inherited cause and enable family testing | Estimate the number of atherogenic lipoprotein particles |
| Preparation | No fasting needed | Often measured with a lipid panel; fasting rules depend on the clinical setting |
A person can have a high apoB level without a pathogenic APOB variant. This is common in insulin resistance and mixed dyslipidemia. A person with an LDL-raising APOB variant may have a lower apoB level after effective medication. The blood marker tracks current particle burden; the gene result explains inherited susceptibility.
After testing, ask the clinician to state which test is being discussed. Confusing “apoB positive” with an APOB pathogenic variant can lead to incorrect family counseling and unnecessary anxiety.
Reconciling discordant lipid markers after an APOB result
An APOB result is most useful when the clinician examines the entire lipoprotein pattern rather than treating LDL cholesterol as the only outcome. LDL-C estimates the cholesterol mass carried inside LDL particles. ApoB reflects the number of atherogenic particles because each LDL, intermediate-density lipoprotein, very-low-density lipoprotein remnant, and lipoprotein(a) particle carries one apoB molecule. Non-HDL cholesterol estimates the cholesterol carried by all apoB-containing particles. These measurements often move together, but they can be discordant.
In insulin resistance, diabetes, hypertriglyceridemia, or metabolic syndrome, a person may have many cholesterol-depleted particles. LDL-C can appear acceptable while apoB remains high, indicating residual particle burden. An LDL-raising APOB binding variant can also produce a pattern resembling familial hypercholesterolemia, but treatment response still must be followed with current biomarkers. The pathogenic variant remains present after statins, ezetimibe, PCSK9-directed therapy, or other lipid-lowering treatment; the falling LDL-C, non-HDL-C, and apoB show that exposure has changed.
Lipoprotein(a) adds another layer. Its apoB-containing particle contributes to the measured apoB concentration, but an elevated Lp(a) is primarily driven by the LPA gene, not by a typical familial-defective-apoB variant. A person can therefore have both an APOB-related disorder and high Lp(a). Measuring Lp(a) at least once can clarify why cardiovascular risk appears greater than expected from LDL-C alone and can refine treatment intensity, even though standard LDL-lowering therapy has a limited effect on Lp(a) concentration.
The interpretation reverses for truncating APOB variants that cause familial hypobetalipoproteinemia. Very low LDL-C and apoB may reduce atherosclerotic risk, but they do not mean the result is harmless. Impaired export of triglyceride from the liver can promote hepatic steatosis. Heterozygous carriers often have few symptoms, yet liver enzymes, metabolic cofactors, alcohol exposure, and imaging may require follow-up. People with biallelic or severe variants can develop fat malabsorption, growth problems, neurologic or retinal complications, and deficiencies of vitamins A, D, E, and K.
Treatment targets therefore cannot be copied from one APOB mechanism to the other. An LDL-receptor-binding defect calls for aggressive reduction of lifelong atherogenic exposure. A truncating variant calls for nutritional assessment and liver surveillance, not an attempt to raise LDL-C to a population average. If a report simply says “pathogenic APOB variant” without explaining whether it impairs receptor binding or shortens apoB, the ordering clinician should request mechanism-specific interpretation before counseling the family.
The family pattern can help confirm the mechanism. Relatives with the LDL-raising form tend to show elevated LDL-C across generations, whereas relatives with a truncating variant often have unusually low total cholesterol and apoB. Laboratory values are not perfectly uniform, but segregation of the expected biochemical phenotype strengthens confidence and helps identify relatives who need early treatment or surveillance.
References
- APOB-Related Familial Hypobetalipoproteinemia 2021 (GeneReviews)
- 2022 Consensus statement on the management of familial hypercholesterolemia in Korea 2022 (Consensus Statement)
- Expanded genetic testing in familial hypercholesterolemia—Clinical implications 2024
- A Comprehensive Review of the Genetics of Dyslipidemias and Familial Hypercholesterolemia: From Pathogenesis to New Therapies 2025 (Review)
- Prevalence and penetrance of pathogenic and likely pathogenic LDLR and APOB gene variants linked to familial hypercholesterolemia and increased risk of coronary artery disease 2025
- Truncating variants in APOB are not VUS when screening for familial hypercholesterolemia 2025
Disclaimer
This article provides general education and does not replace interpretation by a lipid specialist, hepatologist, genetic counselor, or other qualified clinician. Do not start, stop, or change lipid medication or vitamin therapy based only on a genetic report. Chest pain, stroke symptoms, severe weakness, vision change, or signs of liver failure require prompt medical attention.
